Welcome to our dedicated page for Redhill Biopharm news (Ticker: RDHL), a resource for investors and traders seeking the latest updates and insights on Redhill Biopharm stock.
RedHill Biopharma Ltd. develops and commercializes specialty biopharmaceutical products focused on gastrointestinal diseases, infectious diseases and oncology. Its recurring news includes U.S. commercialization activity for Talicia, an FDA-approved all-in-one rifabutin-based therapy for H. pylori infection, as well as updates on joint commercialization through Talicia Holdings Inc.
Company updates also cover clinical and preclinical development across RedHill’s pipeline, including RHB-204 for MAP-related Crohn’s disease research, RHB-102 (Bekinda) for gastrointestinal and oncology-support indications, and opaganib in oncology models and related clinical research. Additional recurring themes include regulatory disclosures, intellectual property, capital-structure matters, governance actions and operating or financial results for the foreign issuer’s ADSs.
RedHill Biopharma has announced the approval of its Phase 2/3 clinical trial for opaganib, targeting severe COVID-19 patients. The trial will enroll up to 270 patients across multiple countries, including Mexico, the UK, and Russia. A parallel Phase 2 study in the U.S. is approximately 50% enrolled and expected to complete this month. If successful, the company plans to submit emergency use applications by Q4 2020. Preliminary results indicate positive outcomes in patients treated with opaganib under compassionate use, with no mechanical ventilation required for these patients.